FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	-

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GOLDSTEIN DOV A MD					2. Issuer Name and Ticker or Trading Symbol Esperion Therapeutics, Inc. [ESPR]									(Check all app		olicable) ctor		Owner	
(Last) (First) (Middle) 888 7TH AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 04/23/2015										Offic belov	er (give title v)	Other below	(specify)		
30TH FLOOR (Street) NEW YORK NY 10106 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indiv ine) X	,				
		Tab	le I - No	n-Deriv	ative	Se	curitie	es Aco	quired,	Dis	posed o	f, c	r Ben	efici	ally	Owne	ed		
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		r) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (Disposed Of (D) (Instr. 3		[A) or 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount		(A) or (D)	Price	е		action(s) 3 and 4)		(Instr. 4)
Common	Stock			04/23/	/2015				S		150,00	0	D	\$10)9.1	1,9	904,594	I	By Aisling Capital II, LP ⁽¹⁾
Common	Stock			04/24/	/2015				S	V	5,743		D	\$1	.08	1,8	398,851	I	By Aisling Capital II, LP ⁽¹⁾
Common Stock			04/24/2015					S	V	61,726 D \$		\$10	06.1	1,837,125		I	By Aisling Capital II, LP ⁽¹⁾		
		Ta	able II -	Derivati (e.g., pu	ive S its, c	ecu alls	urities s, warr	Acqu ants,	ired, D option	ispo	sed of, onvertib	or l	Benef securi	iciall ties)	ly Οι	wned			
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any			saction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		vative irities ired or osed)	Expiration (Month/E	on Dat Day/Ye	ar)	An Se Un De Se	Am or Nu	e and nt of ities lying ative ity (Instr. 3		rice of vative urity tr. 5)	e derivative	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Tit	of le Sha	ares					

Explanation of Responses:

1. The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, and Aisling Capital Partners, LLC ("Aisling Partners"), as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

> 04/27/2015 /s/ Dov Goldstein

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.